RIKEN Immune Regenerative Medicine

There are cases in which a cancer patient is referred to a medical institution under the guise of a free consultation and is billed a high medical fee. This company and its affiliated medical institutions are absolutely not involved in such activities.

ABOUTRIKEN Immune Regenerative Medicine

We develop highly safe drugs and culture methods that are essential for NKT cell-targeted therapy, perform cell cultures under the guidance of affiliated medical institutions, and provide medical treatments that are not covered by insurance to patients.We will continue to expand our network of affiliated medical institutions and further research and development with an emphasis on evidence.

RIKEN Immune Regenerative Medicine Inc. is engaged in two businesses: a drug discovery business (acquired manufacturing and marketing approval based on the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices) and an advanced regenerative medicine business (approval granted for advanced medicine not covered under insurance based on the Act on the Safety of Regenerative Medicine).

SERVICEService

※“RIKNKT” was renamed “RIKEN-NKT” in October 2021.

RIKEN-NKT® is a new standard “immunotherapy” following the three major cancer treatments (surgery, radiotherapy, and anticancer agents).Developed based on NKT cell activation technology that has been researched by public research institutes, the immunotherapy has been commercialized for the first time in Japan through the private sector by RIKEN Immune Regenerative Medicine, a medical technology development company originating from RIKEN. This treatment is completely different from conventional immunotherapy.

What is RIKEN-NKT®

It is the fourth type of lymphocyte after T cells, B cells, and NK cells.The name NKT comes from the fact that it has the characteristics of both NK cells and T cells.NKT cells have a strong immune-response enhancement effect, and by directly killing cancer cells and activating the immune system through IFN-γ production, they exert antitumor effects indirectly.We are developing an immuno-cell therapy that targets NKT cells.

What is NKT cell-targeted therapy?

It has been shown to be highly effective in preventing recurrence.It is a treatment that binds immunologically active substances to dendritic cells cultured after blood collection and returns them to the body, activating NKT cells in the body and exerting an antitumor effect.

September 30, 2022

The homepage was renewed and released.
April 5, 2022

RIKEN Immune Regenerative Medicine, a RIKEN medical company, supported the establishment of the Japan Society for NKT Cell Targeted Therapy.
December 3, 2021

RIKEN Immune Regenerative Medicine Inc. was introduced at an FEC Europe Executive Meeting that was co-sponsored by the French Ambassador to Japan, Philippe Seton, and the International Friendship Exchange Council (FEC).
October 29, 2021

About the publication of the new book “NKT cell-targeted therapy to fight cancer”
October 19, 2021

RIKEN Immune Regenerative Medicine, a RIKEN medical company, supported the start of manufacturing regenerative medicine products (therapeutic drugs) used for cancer immunotherapy for the first time in Okinawa Prefecture.
March 1, 2020

Planned a tie-up with Rosanjin Club Inc. on food, art, exercise, and immune regenerative medicine (including prevention).
April 2, 2018

Our policy (mindset) regarding business partnerships.
July 25, 2016

The homepage has been released.

What immune regenerative medicine
can do for a prosperous future.

LANGUAGE

RIKEN Immune Regenerative Medicine Inc.